Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2011 Financial Results and Reviews Recent Developments
Date:3/14/2012

ensure adequate time for any software download that may be necessary.

About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States, Europe and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena resubmitted to the FDA the lorcaserin NDA in December 2011, and the agency has assigned a new PDUFA target date of June 27, 2012. Eisai Inc. has exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA. An MAA for lorcaserin was filed with the EMA in March 2012. Arena currently owns rights to lorcaserin outside of the United States.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, safety, efficacy, mechanism of action, and potential of lorcaserin; the regulatory review of the lorcaserin NDA resubmission and MAA, including the potential timing for the FDA to complete its review; the data, analyses and other information included in the NDA resubmission,
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Wednesday, March 14
2. Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control
3. Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
4. Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
5. Arena Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
7. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
8. Arena Pharmaceuticals to Present at the Piper Jaffray 23rd Annual Health Care Conference
9. Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
10. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ill., July 25, 2014 NOT FOR ... OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO ... OR REGULATIONS OF SUCH JURISDICTION AbbVie (NYSE: ABBV ... June 30, 2014. "This was another very ... per share above our original guidance and announced plans to ...
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals Holdings ... that will be added to Parnell,s already extensive ... Pty Ltd, a biotechnology company. The compounds now ... shown promise in bone regeneration and dermal regeneration, ... the compounds for the veterinary market with the ...
(Date:7/24/2014)... and MARSEILLE, France , July 24, ... global license from University of Tokyo enables development of ... gene panels, for blood cancers  Mutations of ... favorable prognosis for patients with bone marrow disorders known ... developing companion diagnostics to guide treatment with new anti-cancer ...
Breaking Medicine Technology:AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32AbbVie Reports Second-Quarter 2014 Financial Results 33AbbVie Reports Second-Quarter 2014 Financial Results 34AbbVie Reports Second-Quarter 2014 Financial Results 35AbbVie Reports Second-Quarter 2014 Financial Results 36
... SAN DIEGO, Oct. 29 NuVasive, Inc. (Nasdaq: ... products for minimally disruptive surgical treatments for the spine, ... Executive Vice President, will present at the Oppenheimer 20th ... New York, New York, on Tuesday, November 3, 2009. ...
... , This holiday season, settle your stomach, relieve your wallet ... for the holidays, when many of us may suffer from occasional ... Health finds that you probably don,t need an expensive drug ... new report uses comparative effectiveness research to identify "Best Buys" based ...
Cached Medicine Technology:NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 2NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference 3Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 2Consumer Reports Health: Americans With Heartburn Paying Too Much Green For Nexium's 'Purple Pill' 3
(Date:7/25/2014)... 25, 2014 SF Cable, internet distributor ... in stock and custom-made, delivered at the lowest prices ... announce the availability of its exclusive line of ... angle cables and adapters provide connectivity in the most ... Male A, Male B, Female and Mini 5pin. , ...
(Date:7/25/2014)... July 25, 2014 (HealthDay News) -- Twins, genes may ... environment, according to a new study. Researchers ... putting words together and grammar, were largely inherited. ... the "twinning effect" (a lower level of language performance ... twins than non-identical twins. "This finding disputes hypotheses ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 The Europe ... solutions market in Europe with analysis and forecast of ... $13.53 billion in 2014 to $19.07 billion by 2019, ... , Browse through the TOC of the Europe Cyber ... in-depth analysis provided. It also provides a glimpse of ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines and segments ... forecast of revenue. The artificial lift market in North America ... to around $7 billion by 2018, at a CAGR of ... TOC of North America artificial lift market report, to get ... glimpse of the segmentation in North America Artificial lift market, ...
Breaking Medicine News(10 mins):Health News:SF Cable Presents Exclusive Custom 90° Angle USB Cables and Adaptors 2Health News:Genes May Be Key to Language Delay in Kids 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4
... Funnel Cancer Research to ... ... medical practices in Nevada and SW Utah will benefit from a,new ... Institute (NVCI). The new partnership,will provide resources to help local physicians ...
... new study in the Journal of Communication reveals that ... more than simply providing a list of URLs to accredited sites. ... the second leading cause of cancer death among women. Led by ... out to examine what type of access to internet resources would ...
... WORTH, Texas, July 15 Wound Management,Technologies, Inc., ... a new 510K on a new wound management ... new product (patent pending) will combine the hydrolyzed ... and,will initially be available in gel form. Hydrolyzed ...
... an association between certain past diagnostic radiation procedures and ... rare form of prostate cancer which affects about 10 ... , The study, the first of its kind to ... diagnostic procedures and the risk of prostate cancer, was ...
... Provides consistent information and streamlines service delivery to ... ... Lagan, a provider of enterprise,case management solutions that streamline the delivery ... Lagan Human Services(TM) to support the county,s e-Government,initiative for its Human ...
... survival, study finds , , TUESDAY, July 15 (HealthDay News) ... brain tumors called glioblastoma multiforme (GBM) may help boost ... new report says. , An article in the ... this would mark the first time a tumor-altering therapeutic ...
Cached Medicine News:Health News:Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care 2Health News:Physicians Practice and Nevada Cancer Institute Partner to Improve Patient Care 3Health News:Focused Internet services provide better support to breast cancer patients 2Health News:Wound Management Technologies, Inc. Announces Filing of a 510K 2Health News:Possible link found between X-rays and prostate cancer 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 2Health News:Hennepin County, Minnesota Selects Lagan Human Services(TM) to Support Human Services and Public Health Department e-Government Initiative 3Health News:Brain Cancer Vaccine's Immune Response Key to Outcomes 2
Opti-One multi-purpose solution with citrate protein removal and advanced surfactant combination....
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
Medicine Products: